WuXi set up its corporate venturing unit after the collapse of its $1.6bn merger with Charles River Laboratories in July last year.

Hua Medicine, a China-based drug development and commercialization company, has raised $50m from a consortium including WuXi PharmaTech Corporate Venture. Alongside WuXi (also known as WuXi AppTech) in the round were venture capital firms Arch Venture Partners and Venrock, mutual fund manager Fidelity’s Biosciences and Growth Partners Asia corporate venturing units and Sino-Alliance International. Hua…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.